Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Intracellular sensing of viral genomes and viral evasion

(2019) Hyun-Cheol Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Mitochondria in innate immune signaling

(2018) Balaji Banoth et al.   Translational Research

A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems

(2016) Ivan Lebedev et al.   JOURNAL OF MOLECULAR BIOLOGY

Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease

(2015) Dong Jin Go et al.   RHEUMATOLOGY INTERNATIONAL

The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease

(2013) V. Jovaisaite et al.   JOURNAL OF EXPERIMENTAL BIOLOGY

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment

(2013) A. H. de Wilde et al.   JOURNAL OF GENERAL VIROLOGY

The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors

(2011) Susanne Pfefferle et al.   PLoS Pathogens

Suppression of NF- B by Cyclosporin A and Tacrolimus (FK506) via Induction of the C/EBP Family: Implication for Unfolded Protein Response

(2009) S. Du et al.   JOURNAL OF IMMUNOLOGY

Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction

(2008) Christophe Piot et al.   NEW ENGLAND JOURNAL OF MEDICINE